Cidara Therapeutics

Cidara Therapeutics (CDTX) is using its proprietary Cloud break® platform to develop novel drug-Fc conjugate (DFC) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment.

Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation.

In . . .